How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,738 results for

Psoriasis

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Role of mesenchymal stem cells in the pathogenesis of psoriasis: current perspectives (PubMed)

Role of mesenchymal stem cells in the pathogenesis of psoriasis: current perspectives Mesenchymal stem cells (MSCs) are multipotent nonhematopoietic stromal cells studied for their properties and importance in management of several skin diseases. This review collects and analyzes the emerging published data, which describe the function of MSCs in the pathogenesis of psoriasis.

Full Text available with Trip Pro

2017 Psoriasis (Auckland, N.Z.)

162. The prevalence of cardiovascular diseases risk factors associated with psoriasis in Saudi Arabia (PubMed)

The prevalence of cardiovascular diseases risk factors associated with psoriasis in Saudi Arabia Extensive studies have revealed an increased risk of major adverse cardiac outcomes in patients with severe psoriasis. However, some studies show conflicting results.This study was conducted to assess the CV risk factors in psoriasis patients, and compare it with non-psoriatic patients. In addition, we evaluated if psoriasis is an independent CV risk factor, if its severity can predict CV risk (...) , and if systemic psoriasis treatments modify CV risk.This was a case-control study in 200 participants -100 with psoriasis, and 100 with dermatitis who served as the control. The study was carried out from September 2015 to September 2016. Data was collected using self-administered questionnaires, one each for both groups. Questions include body surface area, current psoriasis/dermatitis therapies, presence of diabetes mellitus, hypertension, smoking history, weight, height, body mass index (BMI), elevated

Full Text available with Trip Pro

2017 Electronic physician

163. Drug-induced psoriasis: clinical perspectives (PubMed)

Drug-induced psoriasis: clinical perspectives Exposure to certain drugs can elicit an induction or exacerbation of psoriasis. Although well-conducted systematic studies on drug-related psoriasis are mostly lacking, traditionally strong associations have been documented for beta-blockers, lithium, antimalarial drugs such as (hydroxy)chloroquine, interferons, imiquimod, and terbinafine. More recently, new associations have been reported for monoclonal antibody- and small-molecule-based targeted (...) therapies used for oncological and immunological indications, such as tumor necrosis factor-alpha antagonists and anti-programmed cell death protein 1 immune checkpoint inhibitors. Recognizing potential drug-related psoriasis is of clinical relevance to allow an optimal management of psoriasis. However, in clinical practice, identifying medication-related exacerbations and induction of psoriasis can be challenging. The clinical and histopathological features of drug-provoked psoriasis may differ little

Full Text available with Trip Pro

2017 Psoriasis (Auckland, N.Z.)

164. Dimethyl fumarate (psoriasis) - Benefit assessment according to §35a Social Code Book V

Dimethyl fumarate (psoriasis) - Benefit assessment according to §35a Social Code Book V Extract 1 Translation of Sections 2.1 to 2.6 of the dossier assessment Dimethylfumarat (Psoriasis vulgaris) – Nutzenbewertung gemäß § 35a SGB V (Version 1.0; Status: 22 December 2017). Please note: This translation is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. IQWiG Reports – Commission No. A17-49 (...) Dimethyl fumarate (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V 1 Extract of dossier assessment A17-49 Version 1.0 Dimethyl fumarate (plaque psoriasis) 22 December 2017 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Dimethyl fumarate (plaque psoriasis) – Benefit assessment according to §35a Social Code Book V Commissioning agency: Federal Joint Committee Commission

2018 Institute for Quality and Efficiency in Healthcare (IQWiG)

165. Local effects of adipose tissue in psoriasis and psoriatic arthritis (PubMed)

Local effects of adipose tissue in psoriasis and psoriatic arthritis The structure and physiological state of the local white adipose tissue (WAT) located underneath the lesional psoriatic skin and inside of the joints affected by psoriatic arthritis play an important role in the pathophysiology of these diseases. WAT pads associated with inflammatory sites in psoriasis and psoriatic arthritis are, correspondingly, dermal WAT and articular adipose tissue; these pads demonstrate inflammatory (...) phenotypes in both diseases. Such local WAT inflammation could be the primary effect in the pathophysiology of psoriasis leading to the modification of the local expression of adipokines, a change in the structure of the basement membrane and the release of keratinocytes with consequent epidermal hyperproliferation during psoriasis. Similar articular adipose tissue inflammation can lead to the induction of structural modifications and synovial inflammation in the joints of patients with psoriatic

Full Text available with Trip Pro

2017 Psoriasis (Auckland, N.Z.)

166. Update on biologic safety for patients with psoriasis during pregnancy (PubMed)

Update on biologic safety for patients with psoriasis during pregnancy Biologic agents have become more common to treat patients with psoriasis, but concerns about their effect on pregnancy and lactation often preclude this treatment during these time periods. During the past decade, we have gained a much better understanding of the course of psoriasis during pregnancy and the safety of the use of biologic agents during pregnancy and lactation. Under certain circumstances, biologic agents can

Full Text available with Trip Pro

2017 International journal of women's dermatology

167. Considerations on biologic agents in psoriasis with the new pregnancy lactation labeling rule (PubMed)

Considerations on biologic agents in psoriasis with the new pregnancy lactation labeling rule 28492043 2018 11 13 2352-6475 3 1 Suppl 2017 Mar International journal of women's dermatology Int J Womens Dermatol Considerations on biologic agents in psoriasis with the new pregnancy lactation labeling rule. S67-S69 10.1016/j.ijwd.2017.02.014 Abrouk Michael M Irvine School of Medicine, University of California, Irvine, CA. Beroukhim Keroush K David Geffen School of Medicine, University of California (...) -Los Angeles, Los Angeles, CA. Nakamura Mio M Department of Dermatology, Psoriasis, and Skin Treatment Center, University of California, San Francisco, CA. Zhu Tian Hao TH Keck School of Medicine, University of Southern California, Los Angeles, CA. Farahnik Benjamin B College of Medicine, University of Vermont, Burlington, VT. Singh Rasnik R David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA. Lee Kristina K Department of Dermatology, Psoriasis, and Skin Treatment

Full Text available with Trip Pro

2017 International journal of women's dermatology

168. Subclinical enthesopathy in patients with psoriasis and its association with other disease parameters: a power Doppler ultrasonographic study (PubMed)

Subclinical enthesopathy in patients with psoriasis and its association with other disease parameters: a power Doppler ultrasonographic study This study aimed to determine the prevalence of subclinical enthesopathy in patients with psoriasis using power Doppler ultrasonography (PDUS) and its association with other disease parameters.A total of 50 patients with psoriasis (31 females) aged 19-70 years underwent a thorough clinical examination that included assessment of body mass index (BMI (...) ) and psoriasis area and severity index (PASI) score. Measurements of inflammatory markers, C-reactive protein (CRP), erythrocyte sedimentation rate (ESR), serum uric acid, and plain radiography of the heels, knees, and sacroiliac joints were performed for all patients. Patients without clinical evidence of arthritis or enthesitis underwent an ultrasonographic (US) examination. According to the US examination, patients were classified into group I (patients with enthesitis) and group II (patients without

Full Text available with Trip Pro

2017 European journal of rheumatology

169. Monitoring treatment response in psoriasis: current perspectives on the clinical utility of reflectance confocal microscopy (PubMed)

Monitoring treatment response in psoriasis: current perspectives on the clinical utility of reflectance confocal microscopy Reflectance confocal microscopy (RCM) evaluation of inflammatory skin diseases represents a relatively new technique that, during the past 5 years, has attracted increasing interest, with consequent progressive increment of publications in literature. The success of RCM is directly related to the high need for noninvasive techniques able to both reduce the number of skin (...) biopsies and support clinical diagnosis and patient management. RCM helps to visualize microscopic descriptors of plaque psoriasis (PP) with good reproducibility between observers and a high grade of correspondence with histopathology. Several clinical tests are used for the therapeutic management of PP, but they are limited by subjective interpretation. Skin biopsy presents objective interpretation, but the procedure is invasive and not repeatable. RCM has been used not only for the evaluation of skin

Full Text available with Trip Pro

2017 Psoriasis (Auckland, N.Z.)

170. Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management (PubMed)

Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management The risk of hepatitis B virus (HBV) reactivation (HBVr) in chronic HBV carriers, in occult HBV patients or in acute HBV patients affected by psoriasis and treated with anti-tumor necrosis factor (TNF)-α agents is a clinical practice issue to face with, particularly if the treatment has a long-term maintenance finality. The aims of this review are to examine the current knowledge on HBVr (...) incidence in chronic HBV carriers and potential occult carriers undergoing therapy with biologics for the treatment of psoriasis and psoriatic arthritis; analyze the prophylactic measure to prevent HBV reactivation and define how to manage HBVr in patients treated with biologics. We searched through PubMed, Google Scholar and Scopus databases and evaluated all published manuscripts concerning HBVr in psoriatic patients, both plaque-type and psoriatic arthritis, in treatment with any indicated anti-TNF-α

Full Text available with Trip Pro

2017 Psoriasis (Auckland, N.Z.)

171. Association Between Skin and Aortic Vascular Inflammation in Patients With Psoriasis: A Case-Cohort Study Using Positron Emission Tomography/Computed Tomography (PubMed)

Association Between Skin and Aortic Vascular Inflammation in Patients With Psoriasis: A Case-Cohort Study Using Positron Emission Tomography/Computed Tomography Inflammation is critical in the development of atherosclerosis. Psoriasis is a chronic inflammatory skin disease that is associated with increased vascular inflammation by 18fluorodeoxyglucose positron emission tomography/computed tomography in vivo and future cardiovascular events. It provides a human model to understand the effect (...) of treating inflammation in a target organ (eg, the skin) on vascular diseases.To investigate the association between change in skin disease severity and change in vascular inflammation at 1 year and to characterize the impact of 1 year of anti-tumor necrosis factor therapy on vascular inflammation.In this prospective cohort study, 220 participants from outpatient practices were recruited at the US National Institutes of Health. A total of 115 consecutively recruited patients with psoriasis were followed

Full Text available with Trip Pro

2017 JAMA cardiology

172. Bone mineral density is lower in male than female patients with plaque-type psoriasis in Iran (PubMed)

Bone mineral density is lower in male than female patients with plaque-type psoriasis in Iran There are many similarities with regard to contributing cytokines in patients with psoriasis and osteoporosis. A theory of probable relationship between these two entities has been proposed but there is no concordant consensus. The aim of this study was to evaluate bone mineral density (BMD) in patients with psoriasis.This cross-sectional study of BMD was conducted with 64 eligible patients (...) with psoriasis who were referred to the dermatology clinic of Razi hospital in Tehran, Iran in between 2011 and 2012.The mean T score of femoral neck was -1.17 and -0.49 in men and women, respectively, which was statistically significant (p = .047). The mean T score of the lumbar spine was -0.93 and -0.30 in men and women, respectively, but not statistically significant (p = .058). In total except with the exclusion of the study site (femur or lumbar), men and women did not have a statistically significant

Full Text available with Trip Pro

2017 International journal of women's dermatology

173. Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management (PubMed)

Nail psoriasis: clinical features, pathogenesis, differential diagnoses, and management Psoriasis is the skin disease that most frequently affects the nails. Depending on the very nail structure involved, different clinical nail alterations can be observed. Irritation of the apical matrix results in psoriatic pits, mid-matrix involvement may cause leukonychia, whole matrix affection may lead to red lunulae or severe nail dystrophy, nail bed involvement may cause salmon spots, subungual (...) hyperkeratosis, and splinter hemorrhages, and psoriasis of the distal nail bed and hyponychium causes onycholysis whereas that of the proximal nail fold causes psoriatic paronychia. The more extensive the involvement, the more severe is the nail destruction. Pustular psoriasis may be seen as yellow spots under the nail or, in case of acrodermatitis continua suppurativa, as an insidious progressive loss of the nail organ. Nail psoriasis has a severe impact on quality of life and may interfere

Full Text available with Trip Pro

2017 Psoriasis (Auckland, N.Z.)

174. Unexplored diversity and strain-level structure of the skin microbiome associated with psoriasis (PubMed)

Unexplored diversity and strain-level structure of the skin microbiome associated with psoriasis Psoriasis is an immune-mediated inflammatory skin disease that has been associated with cutaneous microbial dysbiosis by culture-dependent investigations and rRNA community profiling. We applied, for the first time, high-resolution shotgun metagenomics to characterise the microbiome of psoriatic and unaffected skin from 28 individuals. We demonstrate psoriatic ear sites have a decreased diversity (...) and psoriasis is associated with an increase in Staphylococcus, but overall the microbiomes of psoriatic and unaffected sites display few discriminative features at the species level. Finer strain-level analysis reveals strain heterogeneity colonisation and functional variability providing the intriguing hypothesis of psoriatic niche-specific strain adaptation or selection. Furthermore, we accessed the poorly characterised, but abundant, clades with limited sequence information in public databases

Full Text available with Trip Pro

2017 NPJ biofilms and microbiomes

175. Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis (PubMed)

Clinical utility of ixekizumab in the treatment of moderate-to-severe plaque psoriasis Psoriasis vulgaris is a chronic, immune-mediated systemic disease that affectŝ7.5 million people in the US. It can be treated with many therapies, often in combination, which include topicals, phototherapy, oral systemics, and biologics. Biologic agents target specific components of the immune system involved in the pathogenesis of psoriasis including TNF-alpha, IL-12, IL-17, and IL-23. The biologic (...) ixekizumab, approved for the treatment of moderate-severe plaque psoriasis in the US, targets IL-17. This review describes the role of IL-17 in psoriasis, the mechanism by which ixekizumab targets this cytokine, and the clinical utility of ixekizumab.

Full Text available with Trip Pro

2017 Psoriasis (Auckland, N.Z.)

176. Betamethasone for Adults with Scalp Psoriasis

Betamethasone for Adults with Scalp Psoriasis Disclaimer: The Rapid Response Service is an information service for those involved in planning and providing health care in Canada. Rapid responses are based on a limited literature search and are not comprehensive, systematic reviews. The intent is to provide a list of sources of the best evidence on the topic that CADTH could identify using all reasonable efforts within the time allowed. Rapid responses should be considered along with other types (...) , posted on a web site, redistributed by email or stored on an electronic system without the prior written permission of CADTH or applicable copyright owner. Links: This report may contain links to other information available on the websites of third parties on the Internet. CADTH does not have control over the content of such sites. Use of third party sites is governed by the owners’ own terms and conditions. TITLE: Betamethasone for Adults with Scalp Psoriasis: A Review of the Clinical and Cost

2015 Canadian Agency for Drugs and Technologies in Health - Rapid Review

177. The experience of living with psoriasis: a systematic review and metasynthesis

The experience of living with psoriasis: a systematic review and metasynthesis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2019 PROSPERO

178. Treatments for inverse psoriasis: a systematic review

Treatments for inverse psoriasis: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO

179. Use of placebo as comparator in randomized controlled trials assessing systemic treatments in moderate to severe psoriasis : justification and reporting over time

Use of placebo as comparator in randomized controlled trials assessing systemic treatments in moderate to severe psoriasis : justification and reporting over time Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

180. Systematic review and meta-analysis of oral, periodontal, salivary and temporo-mandibular manifestation of psoriasis

Systematic review and meta-analysis of oral, periodontal, salivary and temporo-mandibular manifestation of psoriasis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>